IO Biotech (IOBT) Competitors $0.92 -0.02 (-2.63%) Closing price 02/12/2025 04:00 PM EasternExtended Trading$0.92 +0.00 (+0.08%) As of 05:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IOBT vs. CCCC, CRDF, ALMS, OGI, LFCR, CGEN, LRMR, AMRN, CTNM, and VIRIShould you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include C4 Therapeutics (CCCC), Cardiff Oncology (CRDF), Alumis (ALMS), Organigram (OGI), Lifecore Biomedical (LFCR), Compugen (CGEN), Larimar Therapeutics (LRMR), Amarin (AMRN), Contineum Therapeutics (CTNM), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical products" industry. IO Biotech vs. C4 Therapeutics Cardiff Oncology Alumis Organigram Lifecore Biomedical Compugen Larimar Therapeutics Amarin Contineum Therapeutics Virios Therapeutics IO Biotech (NASDAQ:IOBT) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Do analysts prefer IOBT or CCCC? IO Biotech currently has a consensus price target of $9.33, indicating a potential upside of 919.70%. C4 Therapeutics has a consensus price target of $11.60, indicating a potential upside of 251.52%. Given IO Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe IO Biotech is more favorable than C4 Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IO Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the MarketBeat Community prefer IOBT or CCCC? C4 Therapeutics received 5 more outperform votes than IO Biotech when rated by MarketBeat users. However, 91.67% of users gave IO Biotech an outperform vote while only 39.13% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformIO BiotechOutperform Votes2291.67% Underperform Votes28.33%C4 TherapeuticsOutperform Votes2739.13% Underperform Votes4260.87% Is IOBT or CCCC more profitable? IO Biotech has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat IO Biotech's return on equity.Company Net Margins Return on Equity Return on Assets IO BiotechN/A -86.56% -75.24% C4 Therapeutics -313.35%-42.45%-27.55% Does the media favor IOBT or CCCC? In the previous week, C4 Therapeutics had 2 more articles in the media than IO Biotech. MarketBeat recorded 3 mentions for C4 Therapeutics and 1 mentions for IO Biotech. IO Biotech's average media sentiment score of 1.43 beat C4 Therapeutics' score of 0.93 indicating that IO Biotech is being referred to more favorably in the media. Company Overall Sentiment IO Biotech Positive C4 Therapeutics Positive Which has more volatility & risk, IOBT or CCCC? IO Biotech has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.95, meaning that its share price is 195% more volatile than the S&P 500. Which has better valuation & earnings, IOBT or CCCC? IO Biotech has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIO BiotechN/AN/A-$86.08M-$1.37-0.67C4 Therapeutics$33.67M6.92-$132.49M-$1.70-1.94 Do insiders & institutionals believe in IOBT or CCCC? 54.8% of IO Biotech shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 2.3% of IO Biotech shares are held by company insiders. Comparatively, 8.6% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryIO Biotech and C4 Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOBT vs. The Competition Export to ExcelMetricIO BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.30M$6.89B$5.66B$9.04BDividend YieldN/A2.90%5.31%4.00%P/E Ratio-0.679.6390.3619.28Price / SalesN/A312.201,035.7479.82Price / CashN/A75.4646.0938.87Price / Book0.455.535.135.00Net Income-$86.08M$123.50M$113.24M$222.75M7 Day Performance-3.55%-4.00%-0.99%-0.57%1 Month Performance5.09%-1.51%4.19%3.00%1 Year Performance-45.84%2.27%21.68%17.85% IO Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOBTIO Biotech3.9111 of 5 stars$0.92-2.6%$9.33+919.7%-45.8%$63.90MN/A0.0030Short Interest ↓Positive NewsGap DownCCCCC4 Therapeutics2.8664 of 5 stars$3.37-5.1%$11.60+244.2%-51.2%$237.89M$20.76M-1.98150Upcoming EarningsShort Interest ↓News CoverageCRDFCardiff Oncology2.2675 of 5 stars$4.58+1.8%$10.33+125.6%+138.5%$234.18M$490,000.00-4.8720Short Interest ↑ALMSAlumisN/A$4.82-15.0%$26.57+451.3%N/A$227.60MN/A0.00N/AOGIOrganigram0.6195 of 5 stars$1.73+3.0%N/A-36.9%$218.26M$117.47M-4.55860Earnings ReportLFCRLifecore Biomedical2.7317 of 5 stars$5.87-0.7%$8.00+36.3%-31.8%$217.37M$128.26M-10.48690Gap DownCGENCompugen2.0147 of 5 stars$2.42-5.8%$4.00+65.3%-6.0%$215.96M$33.46M121.0070LRMRLarimar Therapeutics2.0723 of 5 stars$3.37-2.6%$20.13+497.2%-58.7%$215.04MN/A-2.9330AMRNAmarin0.3964 of 5 stars$0.52-3.3%N/A-53.7%$214.95M$306.91M-5.82360Analyst UpgradeNews CoveragePositive NewsGap DownCTNMContineum Therapeutics2.8845 of 5 stars$8.25-1.9%$29.25+254.5%N/A$212.67M$50M0.0031Short Interest ↓Gap DownVIRIVirios Therapeutics0.1517 of 5 stars$10.74-9.1%$3.00-72.1%+1,675.0%$206.83MN/A-39.785Gap Up Related Companies and Tools Related Companies C4 Therapeutics Competitors Cardiff Oncology Competitors Alumis Competitors Organigram Competitors Lifecore Biomedical Competitors Compugen Competitors Larimar Therapeutics Competitors Amarin Competitors Contineum Therapeutics Competitors Virios Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IOBT) was last updated on 2/13/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.